--- title: "Abbisko’s TGCT Drug Pimicotinib Clears Key Global Milestone With Lancet Phase 3 Publication" type: "News" locale: "en" url: "https://longbridge.com/en/news/278336466.md" description: "Abbisko Cayman Limited's subsidiary, Abbisko Therapeutics, announced the publication of its Phase 3 MANEUVER trial results for pimicotinib in The Lancet. The study demonstrated significant efficacy and a favorable safety profile in treating tenosynovial giant cell tumor, supporting regulatory reviews in China and the U.S. The publication enhances Abbisko's standing in oncology, with potential commercial prospects, although global commercialization remains uncertain. The latest analyst rating for Abbisko Cayman Limited (HK:2256) is a Hold with a price target of HK$13.00." datetime: "2026-03-09T00:08:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278336466.md) - [en](https://longbridge.com/en/news/278336466.md) - [zh-HK](https://longbridge.com/zh-HK/news/278336466.md) --- # Abbisko’s TGCT Drug Pimicotinib Clears Key Global Milestone With Lancet Phase 3 Publication ### Claim 70% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Abbisko Cayman Limited ( (HK:2256) ) has shared an announcement. Abbisko Cayman’s subsidiary Abbisko Therapeutics has reported that results from its global Phase 3 MANEUVER trial of pimicotinib in tenosynovial giant cell tumour have been published in The Lancet, underscoring the quality and robustness of its clinical research. The 94-patient, multicenter study showed significant efficacy and a generally favorable safety profile, supporting China’s 2025 approval, ongoing U.S. and other regulatory reviews, and Merck’s plans to commercialize the drug globally. The publication in a leading international medical journal enhances Abbisko’s academic and clinical standing, potentially strengthening its competitive position in targeted oncology and rare disease treatments. For stakeholders, the data validation and existing China approval highlight near-term commercial prospects, though the company cautions that ultimate global commercialization outcomes remain uncertain and subject to regulatory decisions and market execution. The most recent analyst rating on (HK:2256) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page. **More about Abbisko Cayman Limited** Abbisko Cayman Limited, through its subsidiary Abbisko Therapeutics, operates in the biopharmaceutical industry with a focus on innovative oncology and immunology therapies. The group develops small-molecule drugs such as pimicotinib, a highly selective CSF-1R inhibitor targeting tenosynovial giant cell tumour, and partners with global pharma major Merck for worldwide commercialization. **Average Trading Volume:** 1,568,817 **Technical Sentiment Signal:** Buy **Current Market Cap:** HK$8.08B ### Related Stocks - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [02256.HK](https://longbridge.com/en/quote/02256.HK.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [520500.CN](https://longbridge.com/en/quote/520500.CN.md) - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [562050.CN](https://longbridge.com/en/quote/562050.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [159570.CN](https://longbridge.com/en/quote/159570.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) ## Related News & Research - [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md) - [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md) - [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md) - [Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds](https://longbridge.com/en/news/286487023.md) - [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md)